What it sells
GLP-1 drugs licensed from Hengrui.
Business model breakdown
Workflow: what inputs become what output?
Develops four clinical-stage GLP-1-based candidates; lead Ribupatide (GLP-1/GIP dual agonist) in Phase 3 KaiNETIC with enrollment complete as of September 2026.
Economics: what it saves and how it charges
UnverifiedPre-commercial clinical-stage biotech; no product revenue stated.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2025-10-16 | Series B | CNY 600M | — | pharnexcloud.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.